Profound cell wall remodeling in Candida parapsilosis during systemic infection confers simultaneous tolerance to echinocandins and host immunity
Microbiology Spectrum · 2026
DOI: 10.1128/spectrum.03043-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Farnaz Daneshnia und 28 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biodiversity and Ecosystem Dynamics (IBED), University of Amsterdam, Amsterdam, Netherlands. Hauptthemen laut MEDLINE: Candida parapsilosis, Antifungal Agents, Echinocandins, Cell Wall. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, NIAID NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Antifungal tolerance can promote the emergence of resistance yet often incurs fitness costs for fungal pathogens. How tolerant populations compensate for these deficits and how they may be therapeutically targeted remain poorly understood. Here, we investigate four sequential Candida parapsilosis isolates recovered from a patient with persistent candidemia and failure of micafungin therapy. The infection was ultimately cleared with liposomal amphotericin B (LAMB). Whole-genome sequencing (WGS) confirmed clonal relatedness and the absence of known resistance mutations. Later isolates displayed marked cell wall remodeling (CWR), characterized by increased mannan and reduced β-glucan content, as revealed by microscopy and solid-state nuclear magnetic resonance. These isolates formed thicker biofilms and displayed enhanced echinocandin tolerance but paradoxically showed increased susceptibility to amphotericin B (AMB) in vitro and during systemic infection in mice. Despite a complex mutational landscape, transcriptomic profiling across planktonic and biofilm growth showed minimal divergence from the earliest isolate. Functionally, evolved isolates suppressed M1 macrophage polarization, dampened proinflammatory cytokine production, survived better during neutrophil interactions, and transiently increased fungal burden in vivo . These findings show that host-driven CWR could promote echinocandin tolerance while simultaneously sensitizing C. parapsilosis to AMB. Our results suggest that alternating echinocandin and LAMB therapy may effectively eliminate echinocandin-tolerant fungal populations. IMPORTANCE Antifungal tolerance is increasingly recognized as a precursor to resistance, yet its clinical and biological consequences remain poorly defined. By analyzing sequential Candida parapsilosis isolates from a case of persistent candidemia, we show that cell wall remodeling is associated with echinocandin tolerance, alters host immune interactions, and increases susceptibility to amphotericin B (AMB). These findings reveal how tolerance-associated adaptations shape pathogen fitness during infection and highlight the therapeutic potential of alternating echinocandin and AMB therapy. This work advances our understanding of antifungal tolerance and suggests that exploiting opposing drug susceptibilities may improve treatment outcomes for challenging-to-treat Candida infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biodiversity and Ecosystem Dynamics (IBED), University of Amsterdam, Amsterdam, Netherlands.
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Department of Dermatology, Shanghai Key Laboratory of Molecular Medical Mycology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
- The Center for Fungal Infectious Diseases Basic Research and Innovation of Medicine and Pharmacy, Ministry of Education, Shanghai, China.
- Department of Molecular and Cell Biology, School of Natural Sciences, University of California Merced, Merced, California, USA.
- Department of Chemistry, Michigan State University, East Lansing, Michigan, USA.
ORCID-Profile: Farnaz Daneshnia, Süleyha Hilmioglu-Polat, Louise A Walker, Agostinho Carvalho, Jigar V Desai, David S Perlin, Carol A Munro, Tuo Wang, Wenjie Fang, Clarissa J Nobile, Michael K Mansour, Amir Arastehfar
Förderung
- National Institute of Allergy and Infectious Diseases
- NIAID NIH HHS
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Daneshnia, F., Cai, L., Gunasekaran, D., Gautam, I., Perry, A. M., Mosharaf Ghahfarokhy, P., Ebadati, A., Munoz, J., Padilla, D., Hilmioglu-Polat, S., Mei, S., Floyd, D. J., Schikora-Tamarit, M. À., Fuentes, D., Artigues-Lleixà, M., Walker, L. A., Gonçalves, S. M., Salehi, M., Carvalho, A., …, & Arastehfar, A. (2026). Profound cell wall remodeling in Candida parapsilosis during systemic infection confers simultaneous tolerance to echinocandins and host immunity. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03043-25
Vancouver
Daneshnia F, Cai L, Gunasekaran D, Gautam I, Perry AM, Mosharaf Ghahfarokhy P, et al. Profound cell wall remodeling in Candida parapsilosis during systemic infection confers simultaneous tolerance to echinocandins and host immunity. Microbiology Spectrum. 2026. doi:10.1128/spectrum.03043-25
BibTeX
@article{Daneshnia2026,
author = {Daneshnia, Farnaz and Cai, Liuyang and Gunasekaran, Deepika and Gautam, Isha and Perry, Austin M and Mosharaf Ghahfarokhy, Pegah and Ebadati, Arefeh and Munoz, Julieta and Padilla, Dorian and Hilmioglu-Polat, Süleyha and Mei, Shenglin and Floyd, Daniel J and Schikora-Tamarit, Miquel Àngel and Fuentes, Diego and Artigues-Lleixà, Maria and Walker, Louise A and Gonçalves, Samuel M and Salehi, Mostafa and Carvalho, Agostinho and Desai, Jigar V and Perlin, David S and Munro, Carol A and Hopke, Alex and Wang, Tuo and Gabaldón, Toni and Fang, Wenjie and Nobile, Clarissa J and Mansour, Michael K and Arastehfar, Amir},
title = {Profound cell wall remodeling in Candida parapsilosis during systemic infection confers simultaneous tolerance to echinocandins and host immunity},
journal = {Microbiology Spectrum},
year = {2026},
doi = {10.1128/spectrum.03043-25}
}
EUVIMED